clinical trial · NCT04938830
Clesrovimab (MK-1654) in Infants and Children at Increased Risk for Severe Respiratory Syncytial Virus (RSV) Disease (MK-1654-007)
Merck Sharp & Dohme LLC·phase3·completed·n = 1,003
RSV InfectionClesrovimabPalivizumabPlacebo
brief summary
This study aims to evaluate the safety and tolerability of clesrovimab compared to palivizumab as assessed by the proportion of participants experiencing adverse events (AEs).
started
Nov 30, 2021
primary completion
Apr 28, 2025
completion
Aug 1, 2025
last updated
May 8, 2026
official title
A Phase 3, Multicenter, Randomized, Partially Blinded, Palivizumab- Controlled Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of MK-1654 in Infants and Children at Increased Risk for Severe RSV Disease
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol